Protein Information

ID 18
Name phosphodiesterase
Synonyms CAMP specific phosphodiesterase variant PDE4A 10; CAMP specific phosphodiesterase variant TM3; CAMP specific phosphodiesterase; Cyclic AMP phosphodiesterase PDE4A11; Cyclic AMP specific phosphodiesterase HSPDE4A10; DPDE 2; DPDE2; PDE 4…

Compound Information

ID 1819
Name piperazine
CAS piperazine

Reference

PubMed Abstract RScore(About this table)
11343689 Asomoza-Espinosa R, Alonso-Lopez R, Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Torres-Lopez JE, Granados-Soto V: Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol. 2001 Apr 27;418(3):195-200.
The antinociceptive activity of an inhibitor of phosphodiesterase 5, alone or combined with diclofenac, was assessed in the formalin test. Local administration of diclofenac produced a significant antinociception in both phases of the formalin test in female Wistar rats. In contrast, 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [3,4-d] pyrimidin-5-yl) phenylsulfonyl]-4-methyl piperazine (sildenafil, an inhibitor of phosphodiesterase 5) produced significant antinociception, only during the second phase of the formalin test. Non-effective doses of sildenafil (25-100 microg/paw) significantly increased the antinociceptive effect of an inactive dose of diclofenac (25 microg) in both phases of the test. The antinociception produced by the drugs alone or the combination was due to a local action, as its administration in the contralateral paw was ineffective. Since sildenafil is a potent and selective inhibitor of phosphodiesterase 5, our results suggest that this drug produced its antinociceptive activity, and increased that of diclofenac, probably through the inhibition of cyclic GMP degradation.
83(1,1,1,3)